宁检国 personal page - To The Moon

宁检国

宁检国

.宁检国，初中毕业，务农，为了实现财富自由

174Follow

2Followers

1Topic

0Badge

11-07

$腾盛博药-B(02137)$

2023-05-08

..[可爱] [愤怒] [生气] [惊讶] [白眼] [龇牙] [白眼] ........n bb n.

Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading

2023-05-08

pO[惊讶] [生气] [傲娇] [可爱] [可爱]

Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading

2023-05-08

！！？lm？！：

China Gold (600916): 23Q1 fulfills recovery expectations, layout and breeding diamonds have promising prospects

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585913375465016","uuid":"3585913375465016","gmtCreate":1622822862408,"gmtModify":1624874431927,"name":"宁检国","pinyin":"njgningjianguo","introduction":"","introductionEn":null,"signature":".宁检国，初中毕业，务农，为了实现财富自由","avatar":"https://static.tigerbbs.com/75b5e702e5659469bb94c9e6adbcb55d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":174,"tweetSize":18,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.23","exceedPercentage":"80.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":497570304114744,"gmtCreate":1762500081459,"gmtModify":1762500084149,"author":{"id":"3585913375465016","authorId":"3585913375465016","name":"宁检国","avatar":"https://static.tigerbbs.com/75b5e702e5659469bb94c9e6adbcb55d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585913375465016","idStr":"3585913375465016"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$ &nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$ &nbsp;</a>","text":"$腾盛博药-B(02137)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/497570304114744","isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":656156366,"gmtCreate":1683536400956,"gmtModify":1683536400956,"author":{"id":"3585913375465016","authorId":"3585913375465016","name":"宁检国","avatar":"https://static.tigerbbs.com/75b5e702e5659469bb94c9e6adbcb55d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585913375465016","idStr":"3585913375465016"},"themes":[],"htmlText":"..[可爱]&nbsp;[愤怒]&nbsp;[生气]&nbsp;[惊讶]&nbsp;[白眼]&nbsp;[龇牙]&nbsp;[白眼]&nbsp;........n bb&nbsp; &nbsp; &nbsp; &nbsp; n.","listText":"..[可爱]&nbsp;[愤怒]&nbsp;[生气]&nbsp;[惊讶]&nbsp;[白眼]&nbsp;[龇牙]&nbsp;[白眼]&nbsp;........n bb&nbsp; &nbsp; &nbsp; &nbsp; n.","text":"..[可爱] [愤怒] [生气] [惊讶] [白眼] [龇牙] [白眼] ........n bb n.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/656156366","repostId":"2328760665","repostType":2,"repost":{"id":"2328760665","kind":"news","pubTimestamp":1681969340,"share":"https://ttm.financial/m/news/2328760665?lang=en_US&edition=fundamental","pubTime":"2023-04-20 13:42","market":"hk","language":"zh","title":"Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2328760665","media":"自选股智能写手","summary":"2023年04月20日下午盘13时42分，百心安-B股票出现波动，股价急速下挫5.08%。截至发稿，该股报8.620港元/股，成交量57.86万股，换手率0.24%，振幅6.61%。资金方面，该股资金流入199.558万港元，流出268.074万港元。百心安-B股票所在的医疗保健设备行业中，整体跌幅为0.31%。消息层面，截至13时42分，百心安-B股票正面舆情新闻比例53.85%。","content":"<p><html><body><article>At 13:42 pm on April 20, 2023,<a href=\"https://laohu8.com/S/02185\">Baixinan-B</a>(02185.hk) stocks fluctuated, and the stock price fell sharply by 5.08%. As of press time, the stock was quoted at HK $8.620 per share, with a turnover of 578,600 shares.<span>Turnover rate</span>0.24%, with an amplitude of 6.61%.</p><p>In terms of funds, the stock's capital inflow was 1.99558 million Hong Kong dollars, and the outflow was 2.680,74 million Hong Kong dollars.</p><p>Recent financial report data shows that the stock has achieved<span>Operating income</span>Data is not available yet,<span>Net profit</span>HK $229 million,<span>EARNINGS PER</span>-HK $0.94,<span>GROSS PROFIT</span>Data is not available yet, P/E-9.20 times.</p><p>In terms of institutional ratings, at present, no institution has made \"buy, hold, and sell\" recommendations for the stock.</p><p>In the healthcare equipment industry, where Baixinan-B stock is located, the overall decline was 0.31%. Among its related stocks,<a href=\"https://laohu8.com/S/02297\">Runmed-B</a>、<a href=\"https://laohu8.com/S/00876\">Kaisa Health</a>、<a href=\"https://laohu8.com/S/01612\">Yongsheng Medical</a>Related stocks with larger increases and larger amplitudes include<a href=\"https://laohu8.com/S/01931\">Huajian Medical</a>、<a href=\"https://laohu8.com/S/09955\">Zhiyun Health</a>、<a href=\"https://laohu8.com/S/01066\">Weigao shares</a>With amplitudes of 10.96%, 8.73%, and 6.87%, respectively.</p><p>Baixinan-B Company Profile: Shanghai Baixinan Biotechnology Co., Ltd. is a Chinese company mainly engaged in interventional medicine. The company's main business is the research and development and production of interventional cardiovascular devices. The company's key products include fully degradable stents (BRS) and renal nerve blockade (RDN). The company's products are mainly used to meet the medical needs of the treatment of coronary and peripheral arterial diseases and hypertension.</p><p>At the news level, as of 13:42, the proportion of positive public opinion news on Baixinan-B stock was 53.85%.</p><p>(The above contents are self-selected shares<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>The machine writer Money Call is completed and is only used as a reference for users to read the market, not as a basis for transactions.)</p><p></article></body></html></p>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">自选股智能写手</strong><span class=\"h-time small\">2023-04-20 13:42</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><article>At 13:42 pm on April 20, 2023,<a href=\"https://laohu8.com/S/02185\">Baixinan-B</a>(02185.hk) stocks fluctuated, and the stock price fell sharply by 5.08%. As of press time, the stock was quoted at HK $8.620 per share, with a turnover of 578,600 shares.<span>Turnover rate</span>0.24%, with an amplitude of 6.61%.</p><p>In terms of funds, the stock's capital inflow was 1.99558 million Hong Kong dollars, and the outflow was 2.680,74 million Hong Kong dollars.</p><p>Recent financial report data shows that the stock has achieved<span>Operating income</span>Data is not available yet,<span>Net profit</span>HK $229 million,<span>EARNINGS PER</span>-HK $0.94,<span>GROSS PROFIT</span>Data is not available yet, P/E-9.20 times.</p><p>In terms of institutional ratings, at present, no institution has made \"buy, hold, and sell\" recommendations for the stock.</p><p>In the healthcare equipment industry, where Baixinan-B stock is located, the overall decline was 0.31%. Among its related stocks,<a href=\"https://laohu8.com/S/02297\">Runmed-B</a>、<a href=\"https://laohu8.com/S/00876\">Kaisa Health</a>、<a href=\"https://laohu8.com/S/01612\">Yongsheng Medical</a>Related stocks with larger increases and larger amplitudes include<a href=\"https://laohu8.com/S/01931\">Huajian Medical</a>、<a href=\"https://laohu8.com/S/09955\">Zhiyun Health</a>、<a href=\"https://laohu8.com/S/01066\">Weigao shares</a>With amplitudes of 10.96%, 8.73%, and 6.87%, respectively.</p><p>Baixinan-B Company Profile: Shanghai Baixinan Biotechnology Co., Ltd. is a Chinese company mainly engaged in interventional medicine. The company's main business is the research and development and production of interventional cardiovascular devices. The company's key products include fully degradable stents (BRS) and renal nerve blockade (RDN). The company's products are mainly used to meet the medical needs of the treatment of coronary and peripheral arterial diseases and hypertension.</p><p>At the news level, as of 13:42, the proportion of positive public opinion news on Baixinan-B stock was 53.85%.</p><p>(The above contents are self-selected shares<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>The machine writer Money Call is completed and is only used as a reference for users to read the market, not as a basis for transactions.)</p><p></article></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230420134220846f1c43&s=b\">自选股智能写手</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1100":"医疗保健设备","02185":"百心安-B"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230420134220846f1c43&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2328760665","content_text":"2023年04月20日下午盘13时42分，百心安-B（02185.hk）股票出现波动，股价急速下挫5.08%。截至发稿，该股报8.620港元/股，成交量57.86万股，换手率0.24%，振幅6.61%。资金方面，该股资金流入199.558万港元，流出268.074万港元。最近的财报数据显示，该股实现营业收入数据暂无，净利润-2.29亿港元，每股收益-0.94港元，毛利数据暂无，市盈率-9.20倍。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。百心安-B股票所在的医疗保健设备行业中，整体跌幅为0.31%。其相关个股中，润迈德-B、佳兆业健康、永胜医疗涨幅较大，振幅较大的相关个股有华检医疗、智云健康、威高股份，振幅分别为10.96%、8.73%、6.87%。百心安-B公司简介：上海百心安生物技术有限公司是一家主要从事介入医疗的中国公司。该公司的主营业务是介入式心血管装置的研发和生产。该公司的主要产品包括全降解支架(BRS)和肾神经阻断(RDN)。该公司的产品主要用于满足治疗冠状、外周动脉疾病及高血压等的医疗需求。消息层面，截至13时42分，百心安-B股票正面舆情新闻比例53.85%。（以上内容为自选股智能机器写手Money Call完成，仅作为用户看盘参考，不作为交易依据。）","news_type":1,"symbols_score_info":{"02185":0.9}},"isVote":1,"tweetType":1,"viewCount":1066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":656156987,"gmtCreate":1683536281150,"gmtModify":1683536281150,"author":{"id":"3585913375465016","authorId":"3585913375465016","name":"宁检国","avatar":"https://static.tigerbbs.com/75b5e702e5659469bb94c9e6adbcb55d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585913375465016","idStr":"3585913375465016"},"themes":[],"htmlText":"pO[惊讶]&nbsp;[生气]&nbsp;[傲娇]&nbsp;[可爱]&nbsp;[可爱]&nbsp;","listText":"pO[惊讶]&nbsp;[生气]&nbsp;[傲娇]&nbsp;[可爱]&nbsp;[可爱]&nbsp;","text":"pO[惊讶] [生气] [傲娇] [可爱] [可爱]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/656156987","repostId":"2328760665","repostType":2,"repost":{"id":"2328760665","kind":"news","pubTimestamp":1681969340,"share":"https://ttm.financial/m/news/2328760665?lang=en_US&edition=fundamental","pubTime":"2023-04-20 13:42","market":"hk","language":"zh","title":"Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2328760665","media":"自选股智能写手","summary":"2023年04月20日下午盘13时42分，百心安-B股票出现波动，股价急速下挫5.08%。截至发稿，该股报8.620港元/股，成交量57.86万股，换手率0.24%，振幅6.61%。资金方面，该股资金流入199.558万港元，流出268.074万港元。百心安-B股票所在的医疗保健设备行业中，整体跌幅为0.31%。消息层面，截至13时42分，百心安-B股票正面舆情新闻比例53.85%。","content":"<p><html><body><article>At 13:42 pm on April 20, 2023,<a href=\"https://laohu8.com/S/02185\">Baixinan-B</a>(02185.hk) stocks fluctuated, and the stock price fell sharply by 5.08%. As of press time, the stock was quoted at HK $8.620 per share, with a turnover of 578,600 shares.<span>Turnover rate</span>0.24%, with an amplitude of 6.61%.</p><p>In terms of funds, the stock's capital inflow was 1.99558 million Hong Kong dollars, and the outflow was 2.680,74 million Hong Kong dollars.</p><p>Recent financial report data shows that the stock has achieved<span>Operating income</span>Data is not available yet,<span>Net profit</span>HK $229 million,<span>EARNINGS PER</span>-HK $0.94,<span>GROSS PROFIT</span>Data is not available yet, P/E-9.20 times.</p><p>In terms of institutional ratings, at present, no institution has made \"buy, hold, and sell\" recommendations for the stock.</p><p>In the healthcare equipment industry, where Baixinan-B stock is located, the overall decline was 0.31%. Among its related stocks,<a href=\"https://laohu8.com/S/02297\">Runmed-B</a>、<a href=\"https://laohu8.com/S/00876\">Kaisa Health</a>、<a href=\"https://laohu8.com/S/01612\">Yongsheng Medical</a>Related stocks with larger increases and larger amplitudes include<a href=\"https://laohu8.com/S/01931\">Huajian Medical</a>、<a href=\"https://laohu8.com/S/09955\">Zhiyun Health</a>、<a href=\"https://laohu8.com/S/01066\">Weigao shares</a>With amplitudes of 10.96%, 8.73%, and 6.87%, respectively.</p><p>Baixinan-B Company Profile: Shanghai Baixinan Biotechnology Co., Ltd. is a Chinese company mainly engaged in interventional medicine. The company's main business is the research and development and production of interventional cardiovascular devices. The company's key products include fully degradable stents (BRS) and renal nerve blockade (RDN). The company's products are mainly used to meet the medical needs of the treatment of coronary and peripheral arterial diseases and hypertension.</p><p>At the news level, as of 13:42, the proportion of positive public opinion news on Baixinan-B stock was 53.85%.</p><p>(The above contents are self-selected shares<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>The machine writer Money Call is completed and is only used as a reference for users to read the market, not as a basis for transactions.)</p><p></article></body></html></p>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">自选股智能写手</strong><span class=\"h-time small\">2023-04-20 13:42</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><article>At 13:42 pm on April 20, 2023,<a href=\"https://laohu8.com/S/02185\">Baixinan-B</a>(02185.hk) stocks fluctuated, and the stock price fell sharply by 5.08%. As of press time, the stock was quoted at HK $8.620 per share, with a turnover of 578,600 shares.<span>Turnover rate</span>0.24%, with an amplitude of 6.61%.</p><p>In terms of funds, the stock's capital inflow was 1.99558 million Hong Kong dollars, and the outflow was 2.680,74 million Hong Kong dollars.</p><p>Recent financial report data shows that the stock has achieved<span>Operating income</span>Data is not available yet,<span>Net profit</span>HK $229 million,<span>EARNINGS PER</span>-HK $0.94,<span>GROSS PROFIT</span>Data is not available yet, P/E-9.20 times.</p><p>In terms of institutional ratings, at present, no institution has made \"buy, hold, and sell\" recommendations for the stock.</p><p>In the healthcare equipment industry, where Baixinan-B stock is located, the overall decline was 0.31%. Among its related stocks,<a href=\"https://laohu8.com/S/02297\">Runmed-B</a>、<a href=\"https://laohu8.com/S/00876\">Kaisa Health</a>、<a href=\"https://laohu8.com/S/01612\">Yongsheng Medical</a>Related stocks with larger increases and larger amplitudes include<a href=\"https://laohu8.com/S/01931\">Huajian Medical</a>、<a href=\"https://laohu8.com/S/09955\">Zhiyun Health</a>、<a href=\"https://laohu8.com/S/01066\">Weigao shares</a>With amplitudes of 10.96%, 8.73%, and 6.87%, respectively.</p><p>Baixinan-B Company Profile: Shanghai Baixinan Biotechnology Co., Ltd. is a Chinese company mainly engaged in interventional medicine. The company's main business is the research and development and production of interventional cardiovascular devices. The company's key products include fully degradable stents (BRS) and renal nerve blockade (RDN). The company's products are mainly used to meet the medical needs of the treatment of coronary and peripheral arterial diseases and hypertension.</p><p>At the news level, as of 13:42, the proportion of positive public opinion news on Baixinan-B stock was 53.85%.</p><p>(The above contents are self-selected shares<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>The machine writer Money Call is completed and is only used as a reference for users to read the market, not as a basis for transactions.)</p><p></article></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230420134220846f1c43&s=b\">自选股智能写手</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1100":"医疗保健设备","02185":"百心安-B"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230420134220846f1c43&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2328760665","content_text":"2023年04月20日下午盘13时42分，百心安-B（02185.hk）股票出现波动，股价急速下挫5.08%。截至发稿，该股报8.620港元/股，成交量57.86万股，换手率0.24%，振幅6.61%。资金方面，该股资金流入199.558万港元，流出268.074万港元。最近的财报数据显示，该股实现营业收入数据暂无，净利润-2.29亿港元，每股收益-0.94港元，毛利数据暂无，市盈率-9.20倍。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。百心安-B股票所在的医疗保健设备行业中，整体跌幅为0.31%。其相关个股中，润迈德-B、佳兆业健康、永胜医疗涨幅较大，振幅较大的相关个股有华检医疗、智云健康、威高股份，振幅分别为10.96%、8.73%、6.87%。百心安-B公司简介：上海百心安生物技术有限公司是一家主要从事介入医疗的中国公司。该公司的主营业务是介入式心血管装置的研发和生产。该公司的主要产品包括全降解支架(BRS)和肾神经阻断(RDN)。该公司的产品主要用于满足治疗冠状、外周动脉疾病及高血压等的医疗需求。消息层面，截至13时42分，百心安-B股票正面舆情新闻比例53.85%。（以上内容为自选股智能机器写手Money Call完成，仅作为用户看盘参考，不作为交易依据。）","news_type":1,"symbols_score_info":{"02185":0.9}},"isVote":1,"tweetType":1,"viewCount":1276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":656194066,"gmtCreate":1683511294756,"gmtModify":1683511294756,"author":{"id":"3585913375465016","authorId":"3585913375465016","name":"宁检国","avatar":"https://static.tigerbbs.com/75b5e702e5659469bb94c9e6adbcb55d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585913375465016","idStr":"3585913375465016"},"themes":[],"htmlText":"！！？lm？！&nbsp;：","listText":"！！？lm？！&nbsp;：","text":"！！？lm？！ ：","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/656194066","repostId":"2330393679","repostType":2,"repost":{"id":"2330393679","kind":"news","pubTimestamp":1682511144,"share":"https://ttm.financial/m/news/2330393679?lang=en_US&edition=fundamental","pubTime":"2023-04-26 20:12","market":"sh","language":"zh","title":"China Gold (600916): 23Q1 fulfills recovery expectations, layout and breeding diamonds have promising prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2330393679","media":"西南证券股份有...","summary":"2023Q1 公司实现营收161.4 亿元，同比增长12.3%；实现归母净利润3 亿元，同比增长19.1%，业绩复苏势头明显。2022年公司毛利率为3.9%，同比上升0.8pp，毛利率上升主要受益于公司主营产品盈利能力提升叠加品类结构优化。2023年一季度公司毛利率为4%，同比下降0.1pp。综合来看，2023Q1 公司净利率为1.9%，同比提升0.1pp。积极布局培育钻，有望打造第二增长曲线。预计2023-2025 年EPS 分别为0.61 元、0.76 元、0.86元，对应PE 分别为20 倍、16 倍、14 倍，维持“持有”评级。","content":"<p><html><body><article>Performance summary: The company released its 2022 annual report and 2023 first quarter report. In 2022, the company will achieve revenue of 47.12 billion yuan, a year-on-year decrease of 7.2%; Realize the return to the mother<span>Net profit</span>770 million yuan, a year-on-year decrease of 3.7%. In 2023Q1, the company achieved revenue of 16.14 billion yuan, a year-on-year increase of 12.3%; The net profit attributable to the parent company was 300 million yuan, a year-on-year increase of 19.1%, and the performance recovery momentum was obvious.</p><p>Both profitability and cost control are relatively stable. In 2022, the company's gross profit margin will be 3.9%, a year-on-year increase of 0.8 pp. The increase in gross profit margin is mainly due to the improvement in the profitability of the company's main products and the optimization of the category structure. In terms of products, the gross profit margins of the company's main products gold products/K gold jewelry products are 3.3% (+0.8 pp)/22.2% (+6.4 pp) respectively; In terms of sales models, the gross profit margin of direct sales/distribution in 2022 will be 2.5% (0.8 pp)/6% (1.4 pp) respectively, of which the gross profit margin of direct e-commerce channels will be 3.1%; In terms of expense ratio, the company's total expense ratio was 1.4%, which was flat year-on-year. Looking at the spin-off, the sales expense ratio/administrative expense ratio/R&D expense ratio/financial expense ratio are 1% (+0pp)/0.3% (+0pp)/0.1% (+0pp)/0.1% (-0.1 pp) respectively, and the cost control is relatively stable. On the whole, the company's net in 2022<span>Interest rates</span>It was 1.6%, a year-on-year increase of 0.1 pp. In the first quarter of 2023, the company's gross profit margin was 4%, a year-on-year decrease of 0.1 pp. The total expense ratio was 0.9%, a year-on-year decrease of 0.3 pp; Among them, the sales expense ratio/administrative expense ratio/R&D expense ratio/financial expense ratio were 0.6%/0.2%/0%/0% respectively. Except for the sales expense ratio, which decreased by 0.3 pp year-on-year, the rest remained flat year-on-year. Taken together, the company's net profit margin in 2023Q1 was 1.9%, a year-on-year increase of 0.1 pp.</p><p>The sales structure has been optimized, and North China has the fastest growth under a low base. In 2022, the company's gold products/K gold jewelry products/brand usage fees/brand management fees will be 46.2 billion yuan (-7.7%)/480 million yuan (13.4%)/80 million yuan (-5.8%)/100 million yuan respectively (73.1%), accounting for 98%/1%/0.2%/0.2% of revenue respectively.</p><p>Specifically, the production/sales volume of gold products in 2022 will be 124.8 tons, a year-on-year decrease of 13.5%/12.5% respectively, mainly due to the impact of consumption scenarios and the pressure on consumer demand under the impact of the epidemic in 2022. With the repair of offline consumption scenarios and the improvement of consumer confidence, gold consumption continues to pick up, and performance is expected to usher in improvement. In terms of regions, in 2022, East China/North China/Central China/Southwest China/South China/Northwest China/Northeast China will achieve revenue of 23.34 billion yuan/9.39 billion yuan/3.27 billion yuan/3.05 billion yuan/3.89 billion yuan/2.09 billion yuan/1.84 billion yuan respectively,-0.7%/48.5%/-15.7%/-10%/-56.6%/-13.9%/-14.7% year-on-year respectively.</p><p>Direct sales have strong resilience, and distribution channels continue to be optimized. According to the sales model, in 2022, the company's direct sales/distribution will contribute 28.54 billion yuan (-5.5%)/18.32 billion yuan (-10.4%) in revenue, accounting for 60.9% (+1.3 pp)/39.1% (-1.3 pp) in revenue. 1.3 pp). Specifically, in 2022, the number of direct sales channels will expand by 14 to 105 against the trend, which is one of the reasons for the strong performance resilience of direct sales channels; The company's distribution channels continued to be optimized, and the number of stores decreased by 79 to 3,642 compared with the beginning of the year.</p><p>Actively deploying cultivation diamonds is expected to create a second growth curve. In 2022, the company will strategically enter the cultivation diamond track, and plans to take a multi-pronged approach in the upstream and downstream of the industrial chain. On February 7, 2023, the company will establish a cultivation diamond (new material) promotion division, and actively build a cultivation diamond R&D and design center, display The delivery center and supply chain service center are expected to create the second largest growth curve.</p><p>Earnings forecast and investment advice. It is estimated that the EPS from 2023 to 2025 will be 0.61 yuan, 0.76 yuan, and 0.86 yuan respectively, and the corresponding PE will be 20 times, 16 times, and 14 times respectively, maintaining a \"hold\" rating.</p><p>Risk warning: the risk of gold price fluctuation; The risk of increased competition in the industry; The risk that the company will open stores less quickly than expected.</p><p></article></body></html></p>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Gold (600916): 23Q1 fulfills recovery expectations, layout and breeding diamonds have promising prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Gold (600916): 23Q1 fulfills recovery expectations, layout and breeding diamonds have promising prospects\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">西南证券股份有...</strong><span class=\"h-time small\">2023-04-26 20:12</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><article>Performance summary: The company released its 2022 annual report and 2023 first quarter report. In 2022, the company will achieve revenue of 47.12 billion yuan, a year-on-year decrease of 7.2%; Realize the return to the mother<span>Net profit</span>770 million yuan, a year-on-year decrease of 3.7%. In 2023Q1, the company achieved revenue of 16.14 billion yuan, a year-on-year increase of 12.3%; The net profit attributable to the parent company was 300 million yuan, a year-on-year increase of 19.1%, and the performance recovery momentum was obvious.</p><p>Both profitability and cost control are relatively stable. In 2022, the company's gross profit margin will be 3.9%, a year-on-year increase of 0.8 pp. The increase in gross profit margin is mainly due to the improvement in the profitability of the company's main products and the optimization of the category structure. In terms of products, the gross profit margins of the company's main products gold products/K gold jewelry products are 3.3% (+0.8 pp)/22.2% (+6.4 pp) respectively; In terms of sales models, the gross profit margin of direct sales/distribution in 2022 will be 2.5% (0.8 pp)/6% (1.4 pp) respectively, of which the gross profit margin of direct e-commerce channels will be 3.1%; In terms of expense ratio, the company's total expense ratio was 1.4%, which was flat year-on-year. Looking at the spin-off, the sales expense ratio/administrative expense ratio/R&D expense ratio/financial expense ratio are 1% (+0pp)/0.3% (+0pp)/0.1% (+0pp)/0.1% (-0.1 pp) respectively, and the cost control is relatively stable. On the whole, the company's net in 2022<span>Interest rates</span>It was 1.6%, a year-on-year increase of 0.1 pp. In the first quarter of 2023, the company's gross profit margin was 4%, a year-on-year decrease of 0.1 pp. The total expense ratio was 0.9%, a year-on-year decrease of 0.3 pp; Among them, the sales expense ratio/administrative expense ratio/R&D expense ratio/financial expense ratio were 0.6%/0.2%/0%/0% respectively. Except for the sales expense ratio, which decreased by 0.3 pp year-on-year, the rest remained flat year-on-year. Taken together, the company's net profit margin in 2023Q1 was 1.9%, a year-on-year increase of 0.1 pp.</p><p>The sales structure has been optimized, and North China has the fastest growth under a low base. In 2022, the company's gold products/K gold jewelry products/brand usage fees/brand management fees will be 46.2 billion yuan (-7.7%)/480 million yuan (13.4%)/80 million yuan (-5.8%)/100 million yuan respectively (73.1%), accounting for 98%/1%/0.2%/0.2% of revenue respectively.</p><p>Specifically, the production/sales volume of gold products in 2022 will be 124.8 tons, a year-on-year decrease of 13.5%/12.5% respectively, mainly due to the impact of consumption scenarios and the pressure on consumer demand under the impact of the epidemic in 2022. With the repair of offline consumption scenarios and the improvement of consumer confidence, gold consumption continues to pick up, and performance is expected to usher in improvement. In terms of regions, in 2022, East China/North China/Central China/Southwest China/South China/Northwest China/Northeast China will achieve revenue of 23.34 billion yuan/9.39 billion yuan/3.27 billion yuan/3.05 billion yuan/3.89 billion yuan/2.09 billion yuan/1.84 billion yuan respectively,-0.7%/48.5%/-15.7%/-10%/-56.6%/-13.9%/-14.7% year-on-year respectively.</p><p>Direct sales have strong resilience, and distribution channels continue to be optimized. According to the sales model, in 2022, the company's direct sales/distribution will contribute 28.54 billion yuan (-5.5%)/18.32 billion yuan (-10.4%) in revenue, accounting for 60.9% (+1.3 pp)/39.1% (-1.3 pp) in revenue. 1.3 pp). Specifically, in 2022, the number of direct sales channels will expand by 14 to 105 against the trend, which is one of the reasons for the strong performance resilience of direct sales channels; The company's distribution channels continued to be optimized, and the number of stores decreased by 79 to 3,642 compared with the beginning of the year.</p><p>Actively deploying cultivation diamonds is expected to create a second growth curve. In 2022, the company will strategically enter the cultivation diamond track, and plans to take a multi-pronged approach in the upstream and downstream of the industrial chain. On February 7, 2023, the company will establish a cultivation diamond (new material) promotion division, and actively build a cultivation diamond R&D and design center, display The delivery center and supply chain service center are expected to create the second largest growth curve.</p><p>Earnings forecast and investment advice. It is estimated that the EPS from 2023 to 2025 will be 0.61 yuan, 0.76 yuan, and 0.86 yuan respectively, and the corresponding PE will be 20 times, 16 times, and 14 times respectively, maintaining a \"hold\" rating.</p><p>Risk warning: the risk of gold price fluctuation; The risk of increased competition in the industry; The risk that the company will open stores less quickly than expected.</p><p></article></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230426201228842c0d30&s=b\">西南证券股份有...</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"600916":"中国黄金","BK0209":"零售"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230426201228842c0d30&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2330393679","content_text":"业绩摘要：公司发 布2022年年报及2023年一季报。2022年公司实现营收471.2亿元，同比下降7.2%；实现归母净利润7.7 亿元，同比下降3.7%。2023Q1 公司实现营收161.4 亿元，同比增长12.3%；实现归母净利润3 亿元，同比增长19.1%，业绩复苏势头明显。盈利能力与费控均较为稳健。2022年公司毛利率为3.9%，同比上升0.8pp，毛利率上升主要受益于公司主营产品盈利能力提升叠加品类结构优化。分产品来看，公司主营产品黄金产品/K 金珠宝类产品的毛利率分别为3.3%（+0.8pp）/22.2%（+6.4pp）；分销售模式来看，2022 年直销/经销毛利率分别为2.5%（+0.8pp）/6%（+1.4pp），其中直营电商渠道毛利率为3.1%；费用率方面，公司总费用率为1.4%，同比持平。分拆来看，销售费用率/管理费用率/研发费用率/财务费用率分别为1%（+0pp）/0.3%（+0pp）/0.1%（+0pp）/0.1%（-0.1 pp），费控较为稳健。综合来看，2022 年公司净利率为1.6%，同比上升0.1pp。2023年一季度公司毛利率为4%，同比下降0.1pp。总费用率为0.9%，同比下降0.3pp；其中销售费用率/ 管理费用率/ 研发费用率/ 财务费用率分别为0.6%/0.2%/0%/0%，除销售费用率同比下降0.3pp 外，其余同比持平。综合来看，2023Q1 公司净利率为1.9%，同比提升0.1pp。销售结构有所优化，低基数下华北地区增长最快。2022年公司黄金产品/K 金珠宝产品/品牌使用费/品牌管理费分别为462 亿元（-7.7%）/4.8亿元（+13.4%）/0.8 亿元（-5.8%）/1亿元（+73.1%），营收占比分别为98%/1%/0.2%/0.2%。具体来看，2022 年黄金产品生产量/销售量均为124.8 吨，分别同比下滑13.5%/12.5%，主要受2022年在疫情冲击下消费场景及消费需求承压影响，2023年以来随着线下消费场景修复及消费信心改善，黄金消费持续回暖，预计业绩会迎来改善。分地区来看，2022 年华东/华北/华中/西南/华南/西北/东北地区分别实现营收233.4亿元/93.9亿元/32.7亿元/30.5亿元/38.9亿元/20.9亿元/18.4亿元，分别同比-0.7%/+48.5%/-15.7%/-10%/-56.6%/-13.9%/-14.7%，华北地区在低基数下增长最快。直营韧性较强，经销渠道持续优化。按销售模式来看，2022 年公司直销/经销分别贡献收入285.4 亿元（-5.5%）/183.2 亿元（-10.4%），营收占比分别为60.9%（+1.3pp）/39.1%（-1.3pp）。具体来看，2022 年直营渠道逆势扩张14家至105家，是直营渠道业绩韧性较强的原因之一；公司经销渠道持续优化，门店数量较年初净减少79家至3642 家。积极布局培育钻，有望打造第二增长曲线。2022 年公司战略性切入培育钻赛道，计划在产业链上下游多管齐下，并于2023 年2 月7日成立培育钻石（新材料）推广事业部，积极建设培育钻研发设计中心、展示交付中心和供应链服务中心，有望打造第二大增长曲线。盈利预测与投资建议。预计2023-2025 年EPS 分别为0.61 元、0.76 元、0.86元，对应PE 分别为20 倍、16 倍、14 倍，维持“持有”评级。风险提示：金价波动的风险；行业竞争加剧的风险；公司开店速度不及预期的风险。","news_type":1,"symbols_score_info":{"600916":0.9}},"isVote":1,"tweetType":1,"viewCount":1228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":497570304114744,"gmtCreate":1762500081459,"gmtModify":1762500084149,"author":{"id":"3585913375465016","authorId":"3585913375465016","name":"宁检国","avatar":"https://static.tigerbbs.com/75b5e702e5659469bb94c9e6adbcb55d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585913375465016","idStr":"3585913375465016"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$ &nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$ &nbsp;</a>","text":"$腾盛博药-B(02137)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/497570304114744","isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":656156366,"gmtCreate":1683536400956,"gmtModify":1683536400956,"author":{"id":"3585913375465016","authorId":"3585913375465016","name":"宁检国","avatar":"https://static.tigerbbs.com/75b5e702e5659469bb94c9e6adbcb55d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585913375465016","idStr":"3585913375465016"},"themes":[],"htmlText":"..[可爱]&nbsp;[愤怒]&nbsp;[生气]&nbsp;[惊讶]&nbsp;[白眼]&nbsp;[龇牙]&nbsp;[白眼]&nbsp;........n bb&nbsp; &nbsp; &nbsp; &nbsp; n.","listText":"..[可爱]&nbsp;[愤怒]&nbsp;[生气]&nbsp;[惊讶]&nbsp;[白眼]&nbsp;[龇牙]&nbsp;[白眼]&nbsp;........n bb&nbsp; &nbsp; &nbsp; &nbsp; n.","text":"..[可爱] [愤怒] [生气] [惊讶] [白眼] [龇牙] [白眼] ........n bb n.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/656156366","repostId":"2328760665","repostType":2,"repost":{"id":"2328760665","kind":"news","pubTimestamp":1681969340,"share":"https://ttm.financial/m/news/2328760665?lang=en_US&edition=fundamental","pubTime":"2023-04-20 13:42","market":"hk","language":"zh","title":"Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2328760665","media":"自选股智能写手","summary":"2023年04月20日下午盘13时42分，百心安-B股票出现波动，股价急速下挫5.08%。截至发稿，该股报8.620港元/股，成交量57.86万股，换手率0.24%，振幅6.61%。资金方面，该股资金流入199.558万港元，流出268.074万港元。百心安-B股票所在的医疗保健设备行业中，整体跌幅为0.31%。消息层面，截至13时42分，百心安-B股票正面舆情新闻比例53.85%。","content":"<p><html><body><article>At 13:42 pm on April 20, 2023,<a href=\"https://laohu8.com/S/02185\">Baixinan-B</a>(02185.hk) stocks fluctuated, and the stock price fell sharply by 5.08%. As of press time, the stock was quoted at HK $8.620 per share, with a turnover of 578,600 shares.<span>Turnover rate</span>0.24%, with an amplitude of 6.61%.</p><p>In terms of funds, the stock's capital inflow was 1.99558 million Hong Kong dollars, and the outflow was 2.680,74 million Hong Kong dollars.</p><p>Recent financial report data shows that the stock has achieved<span>Operating income</span>Data is not available yet,<span>Net profit</span>HK $229 million,<span>EARNINGS PER</span>-HK $0.94,<span>GROSS PROFIT</span>Data is not available yet, P/E-9.20 times.</p><p>In terms of institutional ratings, at present, no institution has made \"buy, hold, and sell\" recommendations for the stock.</p><p>In the healthcare equipment industry, where Baixinan-B stock is located, the overall decline was 0.31%. Among its related stocks,<a href=\"https://laohu8.com/S/02297\">Runmed-B</a>、<a href=\"https://laohu8.com/S/00876\">Kaisa Health</a>、<a href=\"https://laohu8.com/S/01612\">Yongsheng Medical</a>Related stocks with larger increases and larger amplitudes include<a href=\"https://laohu8.com/S/01931\">Huajian Medical</a>、<a href=\"https://laohu8.com/S/09955\">Zhiyun Health</a>、<a href=\"https://laohu8.com/S/01066\">Weigao shares</a>With amplitudes of 10.96%, 8.73%, and 6.87%, respectively.</p><p>Baixinan-B Company Profile: Shanghai Baixinan Biotechnology Co., Ltd. is a Chinese company mainly engaged in interventional medicine. The company's main business is the research and development and production of interventional cardiovascular devices. The company's key products include fully degradable stents (BRS) and renal nerve blockade (RDN). The company's products are mainly used to meet the medical needs of the treatment of coronary and peripheral arterial diseases and hypertension.</p><p>At the news level, as of 13:42, the proportion of positive public opinion news on Baixinan-B stock was 53.85%.</p><p>(The above contents are self-selected shares<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>The machine writer Money Call is completed and is only used as a reference for users to read the market, not as a basis for transactions.)</p><p></article></body></html></p>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">自选股智能写手</strong><span class=\"h-time small\">2023-04-20 13:42</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><article>At 13:42 pm on April 20, 2023,<a href=\"https://laohu8.com/S/02185\">Baixinan-B</a>(02185.hk) stocks fluctuated, and the stock price fell sharply by 5.08%. As of press time, the stock was quoted at HK $8.620 per share, with a turnover of 578,600 shares.<span>Turnover rate</span>0.24%, with an amplitude of 6.61%.</p><p>In terms of funds, the stock's capital inflow was 1.99558 million Hong Kong dollars, and the outflow was 2.680,74 million Hong Kong dollars.</p><p>Recent financial report data shows that the stock has achieved<span>Operating income</span>Data is not available yet,<span>Net profit</span>HK $229 million,<span>EARNINGS PER</span>-HK $0.94,<span>GROSS PROFIT</span>Data is not available yet, P/E-9.20 times.</p><p>In terms of institutional ratings, at present, no institution has made \"buy, hold, and sell\" recommendations for the stock.</p><p>In the healthcare equipment industry, where Baixinan-B stock is located, the overall decline was 0.31%. Among its related stocks,<a href=\"https://laohu8.com/S/02297\">Runmed-B</a>、<a href=\"https://laohu8.com/S/00876\">Kaisa Health</a>、<a href=\"https://laohu8.com/S/01612\">Yongsheng Medical</a>Related stocks with larger increases and larger amplitudes include<a href=\"https://laohu8.com/S/01931\">Huajian Medical</a>、<a href=\"https://laohu8.com/S/09955\">Zhiyun Health</a>、<a href=\"https://laohu8.com/S/01066\">Weigao shares</a>With amplitudes of 10.96%, 8.73%, and 6.87%, respectively.</p><p>Baixinan-B Company Profile: Shanghai Baixinan Biotechnology Co., Ltd. is a Chinese company mainly engaged in interventional medicine. The company's main business is the research and development and production of interventional cardiovascular devices. The company's key products include fully degradable stents (BRS) and renal nerve blockade (RDN). The company's products are mainly used to meet the medical needs of the treatment of coronary and peripheral arterial diseases and hypertension.</p><p>At the news level, as of 13:42, the proportion of positive public opinion news on Baixinan-B stock was 53.85%.</p><p>(The above contents are self-selected shares<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>The machine writer Money Call is completed and is only used as a reference for users to read the market, not as a basis for transactions.)</p><p></article></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230420134220846f1c43&s=b\">自选股智能写手</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1100":"医疗保健设备","02185":"百心安-B"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230420134220846f1c43&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2328760665","content_text":"2023年04月20日下午盘13时42分，百心安-B（02185.hk）股票出现波动，股价急速下挫5.08%。截至发稿，该股报8.620港元/股，成交量57.86万股，换手率0.24%，振幅6.61%。资金方面，该股资金流入199.558万港元，流出268.074万港元。最近的财报数据显示，该股实现营业收入数据暂无，净利润-2.29亿港元，每股收益-0.94港元，毛利数据暂无，市盈率-9.20倍。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。百心安-B股票所在的医疗保健设备行业中，整体跌幅为0.31%。其相关个股中，润迈德-B、佳兆业健康、永胜医疗涨幅较大，振幅较大的相关个股有华检医疗、智云健康、威高股份，振幅分别为10.96%、8.73%、6.87%。百心安-B公司简介：上海百心安生物技术有限公司是一家主要从事介入医疗的中国公司。该公司的主营业务是介入式心血管装置的研发和生产。该公司的主要产品包括全降解支架(BRS)和肾神经阻断(RDN)。该公司的产品主要用于满足治疗冠状、外周动脉疾病及高血压等的医疗需求。消息层面，截至13时42分，百心安-B股票正面舆情新闻比例53.85%。（以上内容为自选股智能机器写手Money Call完成，仅作为用户看盘参考，不作为交易依据。）","news_type":1,"symbols_score_info":{"02185":0.9}},"isVote":1,"tweetType":1,"viewCount":1066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":656156987,"gmtCreate":1683536281150,"gmtModify":1683536281150,"author":{"id":"3585913375465016","authorId":"3585913375465016","name":"宁检国","avatar":"https://static.tigerbbs.com/75b5e702e5659469bb94c9e6adbcb55d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585913375465016","idStr":"3585913375465016"},"themes":[],"htmlText":"pO[惊讶]&nbsp;[生气]&nbsp;[傲娇]&nbsp;[可爱]&nbsp;[可爱]&nbsp;","listText":"pO[惊讶]&nbsp;[生气]&nbsp;[傲娇]&nbsp;[可爱]&nbsp;[可爱]&nbsp;","text":"pO[惊讶] [生气] [傲娇] [可爱] [可爱]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/656156987","repostId":"2328760665","repostType":2,"repost":{"id":"2328760665","kind":"news","pubTimestamp":1681969340,"share":"https://ttm.financial/m/news/2328760665?lang=en_US&edition=fundamental","pubTime":"2023-04-20 13:42","market":"hk","language":"zh","title":"Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2328760665","media":"自选股智能写手","summary":"2023年04月20日下午盘13时42分，百心安-B股票出现波动，股价急速下挫5.08%。截至发稿，该股报8.620港元/股，成交量57.86万股，换手率0.24%，振幅6.61%。资金方面，该股资金流入199.558万港元，流出268.074万港元。百心安-B股票所在的医疗保健设备行业中，整体跌幅为0.31%。消息层面，截至13时42分，百心安-B股票正面舆情新闻比例53.85%。","content":"<p><html><body><article>At 13:42 pm on April 20, 2023,<a href=\"https://laohu8.com/S/02185\">Baixinan-B</a>(02185.hk) stocks fluctuated, and the stock price fell sharply by 5.08%. As of press time, the stock was quoted at HK $8.620 per share, with a turnover of 578,600 shares.<span>Turnover rate</span>0.24%, with an amplitude of 6.61%.</p><p>In terms of funds, the stock's capital inflow was 1.99558 million Hong Kong dollars, and the outflow was 2.680,74 million Hong Kong dollars.</p><p>Recent financial report data shows that the stock has achieved<span>Operating income</span>Data is not available yet,<span>Net profit</span>HK $229 million,<span>EARNINGS PER</span>-HK $0.94,<span>GROSS PROFIT</span>Data is not available yet, P/E-9.20 times.</p><p>In terms of institutional ratings, at present, no institution has made \"buy, hold, and sell\" recommendations for the stock.</p><p>In the healthcare equipment industry, where Baixinan-B stock is located, the overall decline was 0.31%. Among its related stocks,<a href=\"https://laohu8.com/S/02297\">Runmed-B</a>、<a href=\"https://laohu8.com/S/00876\">Kaisa Health</a>、<a href=\"https://laohu8.com/S/01612\">Yongsheng Medical</a>Related stocks with larger increases and larger amplitudes include<a href=\"https://laohu8.com/S/01931\">Huajian Medical</a>、<a href=\"https://laohu8.com/S/09955\">Zhiyun Health</a>、<a href=\"https://laohu8.com/S/01066\">Weigao shares</a>With amplitudes of 10.96%, 8.73%, and 6.87%, respectively.</p><p>Baixinan-B Company Profile: Shanghai Baixinan Biotechnology Co., Ltd. is a Chinese company mainly engaged in interventional medicine. The company's main business is the research and development and production of interventional cardiovascular devices. The company's key products include fully degradable stents (BRS) and renal nerve blockade (RDN). The company's products are mainly used to meet the medical needs of the treatment of coronary and peripheral arterial diseases and hypertension.</p><p>At the news level, as of 13:42, the proportion of positive public opinion news on Baixinan-B stock was 53.85%.</p><p>(The above contents are self-selected shares<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>The machine writer Money Call is completed and is only used as a reference for users to read the market, not as a basis for transactions.)</p><p></article></body></html></p>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaixinan-B intraday changes, share price fell 5.08% to HK $8.620 in afternoon trading\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">自选股智能写手</strong><span class=\"h-time small\">2023-04-20 13:42</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><article>At 13:42 pm on April 20, 2023,<a href=\"https://laohu8.com/S/02185\">Baixinan-B</a>(02185.hk) stocks fluctuated, and the stock price fell sharply by 5.08%. As of press time, the stock was quoted at HK $8.620 per share, with a turnover of 578,600 shares.<span>Turnover rate</span>0.24%, with an amplitude of 6.61%.</p><p>In terms of funds, the stock's capital inflow was 1.99558 million Hong Kong dollars, and the outflow was 2.680,74 million Hong Kong dollars.</p><p>Recent financial report data shows that the stock has achieved<span>Operating income</span>Data is not available yet,<span>Net profit</span>HK $229 million,<span>EARNINGS PER</span>-HK $0.94,<span>GROSS PROFIT</span>Data is not available yet, P/E-9.20 times.</p><p>In terms of institutional ratings, at present, no institution has made \"buy, hold, and sell\" recommendations for the stock.</p><p>In the healthcare equipment industry, where Baixinan-B stock is located, the overall decline was 0.31%. Among its related stocks,<a href=\"https://laohu8.com/S/02297\">Runmed-B</a>、<a href=\"https://laohu8.com/S/00876\">Kaisa Health</a>、<a href=\"https://laohu8.com/S/01612\">Yongsheng Medical</a>Related stocks with larger increases and larger amplitudes include<a href=\"https://laohu8.com/S/01931\">Huajian Medical</a>、<a href=\"https://laohu8.com/S/09955\">Zhiyun Health</a>、<a href=\"https://laohu8.com/S/01066\">Weigao shares</a>With amplitudes of 10.96%, 8.73%, and 6.87%, respectively.</p><p>Baixinan-B Company Profile: Shanghai Baixinan Biotechnology Co., Ltd. is a Chinese company mainly engaged in interventional medicine. The company's main business is the research and development and production of interventional cardiovascular devices. The company's key products include fully degradable stents (BRS) and renal nerve blockade (RDN). The company's products are mainly used to meet the medical needs of the treatment of coronary and peripheral arterial diseases and hypertension.</p><p>At the news level, as of 13:42, the proportion of positive public opinion news on Baixinan-B stock was 53.85%.</p><p>(The above contents are self-selected shares<a href=\"https://laohu8.com/S/5RE.SI\">smart</a>The machine writer Money Call is completed and is only used as a reference for users to read the market, not as a basis for transactions.)</p><p></article></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230420134220846f1c43&s=b\">自选股智能写手</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1100":"医疗保健设备","02185":"百心安-B"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230420134220846f1c43&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2328760665","content_text":"2023年04月20日下午盘13时42分，百心安-B（02185.hk）股票出现波动，股价急速下挫5.08%。截至发稿，该股报8.620港元/股，成交量57.86万股，换手率0.24%，振幅6.61%。资金方面，该股资金流入199.558万港元，流出268.074万港元。最近的财报数据显示，该股实现营业收入数据暂无，净利润-2.29亿港元，每股收益-0.94港元，毛利数据暂无，市盈率-9.20倍。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。百心安-B股票所在的医疗保健设备行业中，整体跌幅为0.31%。其相关个股中，润迈德-B、佳兆业健康、永胜医疗涨幅较大，振幅较大的相关个股有华检医疗、智云健康、威高股份，振幅分别为10.96%、8.73%、6.87%。百心安-B公司简介：上海百心安生物技术有限公司是一家主要从事介入医疗的中国公司。该公司的主营业务是介入式心血管装置的研发和生产。该公司的主要产品包括全降解支架(BRS)和肾神经阻断(RDN)。该公司的产品主要用于满足治疗冠状、外周动脉疾病及高血压等的医疗需求。消息层面，截至13时42分，百心安-B股票正面舆情新闻比例53.85%。（以上内容为自选股智能机器写手Money Call完成，仅作为用户看盘参考，不作为交易依据。）","news_type":1,"symbols_score_info":{"02185":0.9}},"isVote":1,"tweetType":1,"viewCount":1276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":656194066,"gmtCreate":1683511294756,"gmtModify":1683511294756,"author":{"id":"3585913375465016","authorId":"3585913375465016","name":"宁检国","avatar":"https://static.tigerbbs.com/75b5e702e5659469bb94c9e6adbcb55d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585913375465016","idStr":"3585913375465016"},"themes":[],"htmlText":"！！？lm？！&nbsp;：","listText":"！！？lm？！&nbsp;：","text":"！！？lm？！ ：","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/656194066","repostId":"2330393679","repostType":2,"repost":{"id":"2330393679","kind":"news","pubTimestamp":1682511144,"share":"https://ttm.financial/m/news/2330393679?lang=en_US&edition=fundamental","pubTime":"2023-04-26 20:12","market":"sh","language":"zh","title":"China Gold (600916): 23Q1 fulfills recovery expectations, layout and breeding diamonds have promising prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2330393679","media":"西南证券股份有...","summary":"2023Q1 公司实现营收161.4 亿元，同比增长12.3%；实现归母净利润3 亿元，同比增长19.1%，业绩复苏势头明显。2022年公司毛利率为3.9%，同比上升0.8pp，毛利率上升主要受益于公司主营产品盈利能力提升叠加品类结构优化。2023年一季度公司毛利率为4%，同比下降0.1pp。综合来看，2023Q1 公司净利率为1.9%，同比提升0.1pp。积极布局培育钻，有望打造第二增长曲线。预计2023-2025 年EPS 分别为0.61 元、0.76 元、0.86元，对应PE 分别为20 倍、16 倍、14 倍，维持“持有”评级。","content":"<p><html><body><article>Performance summary: The company released its 2022 annual report and 2023 first quarter report. In 2022, the company will achieve revenue of 47.12 billion yuan, a year-on-year decrease of 7.2%; Realize the return to the mother<span>Net profit</span>770 million yuan, a year-on-year decrease of 3.7%. In 2023Q1, the company achieved revenue of 16.14 billion yuan, a year-on-year increase of 12.3%; The net profit attributable to the parent company was 300 million yuan, a year-on-year increase of 19.1%, and the performance recovery momentum was obvious.</p><p>Both profitability and cost control are relatively stable. In 2022, the company's gross profit margin will be 3.9%, a year-on-year increase of 0.8 pp. The increase in gross profit margin is mainly due to the improvement in the profitability of the company's main products and the optimization of the category structure. In terms of products, the gross profit margins of the company's main products gold products/K gold jewelry products are 3.3% (+0.8 pp)/22.2% (+6.4 pp) respectively; In terms of sales models, the gross profit margin of direct sales/distribution in 2022 will be 2.5% (0.8 pp)/6% (1.4 pp) respectively, of which the gross profit margin of direct e-commerce channels will be 3.1%; In terms of expense ratio, the company's total expense ratio was 1.4%, which was flat year-on-year. Looking at the spin-off, the sales expense ratio/administrative expense ratio/R&D expense ratio/financial expense ratio are 1% (+0pp)/0.3% (+0pp)/0.1% (+0pp)/0.1% (-0.1 pp) respectively, and the cost control is relatively stable. On the whole, the company's net in 2022<span>Interest rates</span>It was 1.6%, a year-on-year increase of 0.1 pp. In the first quarter of 2023, the company's gross profit margin was 4%, a year-on-year decrease of 0.1 pp. The total expense ratio was 0.9%, a year-on-year decrease of 0.3 pp; Among them, the sales expense ratio/administrative expense ratio/R&D expense ratio/financial expense ratio were 0.6%/0.2%/0%/0% respectively. Except for the sales expense ratio, which decreased by 0.3 pp year-on-year, the rest remained flat year-on-year. Taken together, the company's net profit margin in 2023Q1 was 1.9%, a year-on-year increase of 0.1 pp.</p><p>The sales structure has been optimized, and North China has the fastest growth under a low base. In 2022, the company's gold products/K gold jewelry products/brand usage fees/brand management fees will be 46.2 billion yuan (-7.7%)/480 million yuan (13.4%)/80 million yuan (-5.8%)/100 million yuan respectively (73.1%), accounting for 98%/1%/0.2%/0.2% of revenue respectively.</p><p>Specifically, the production/sales volume of gold products in 2022 will be 124.8 tons, a year-on-year decrease of 13.5%/12.5% respectively, mainly due to the impact of consumption scenarios and the pressure on consumer demand under the impact of the epidemic in 2022. With the repair of offline consumption scenarios and the improvement of consumer confidence, gold consumption continues to pick up, and performance is expected to usher in improvement. In terms of regions, in 2022, East China/North China/Central China/Southwest China/South China/Northwest China/Northeast China will achieve revenue of 23.34 billion yuan/9.39 billion yuan/3.27 billion yuan/3.05 billion yuan/3.89 billion yuan/2.09 billion yuan/1.84 billion yuan respectively,-0.7%/48.5%/-15.7%/-10%/-56.6%/-13.9%/-14.7% year-on-year respectively.</p><p>Direct sales have strong resilience, and distribution channels continue to be optimized. According to the sales model, in 2022, the company's direct sales/distribution will contribute 28.54 billion yuan (-5.5%)/18.32 billion yuan (-10.4%) in revenue, accounting for 60.9% (+1.3 pp)/39.1% (-1.3 pp) in revenue. 1.3 pp). Specifically, in 2022, the number of direct sales channels will expand by 14 to 105 against the trend, which is one of the reasons for the strong performance resilience of direct sales channels; The company's distribution channels continued to be optimized, and the number of stores decreased by 79 to 3,642 compared with the beginning of the year.</p><p>Actively deploying cultivation diamonds is expected to create a second growth curve. In 2022, the company will strategically enter the cultivation diamond track, and plans to take a multi-pronged approach in the upstream and downstream of the industrial chain. On February 7, 2023, the company will establish a cultivation diamond (new material) promotion division, and actively build a cultivation diamond R&D and design center, display The delivery center and supply chain service center are expected to create the second largest growth curve.</p><p>Earnings forecast and investment advice. It is estimated that the EPS from 2023 to 2025 will be 0.61 yuan, 0.76 yuan, and 0.86 yuan respectively, and the corresponding PE will be 20 times, 16 times, and 14 times respectively, maintaining a \"hold\" rating.</p><p>Risk warning: the risk of gold price fluctuation; The risk of increased competition in the industry; The risk that the company will open stores less quickly than expected.</p><p></article></body></html></p>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Gold (600916): 23Q1 fulfills recovery expectations, layout and breeding diamonds have promising prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Gold (600916): 23Q1 fulfills recovery expectations, layout and breeding diamonds have promising prospects\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">西南证券股份有...</strong><span class=\"h-time small\">2023-04-26 20:12</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><article>Performance summary: The company released its 2022 annual report and 2023 first quarter report. In 2022, the company will achieve revenue of 47.12 billion yuan, a year-on-year decrease of 7.2%; Realize the return to the mother<span>Net profit</span>770 million yuan, a year-on-year decrease of 3.7%. In 2023Q1, the company achieved revenue of 16.14 billion yuan, a year-on-year increase of 12.3%; The net profit attributable to the parent company was 300 million yuan, a year-on-year increase of 19.1%, and the performance recovery momentum was obvious.</p><p>Both profitability and cost control are relatively stable. In 2022, the company's gross profit margin will be 3.9%, a year-on-year increase of 0.8 pp. The increase in gross profit margin is mainly due to the improvement in the profitability of the company's main products and the optimization of the category structure. In terms of products, the gross profit margins of the company's main products gold products/K gold jewelry products are 3.3% (+0.8 pp)/22.2% (+6.4 pp) respectively; In terms of sales models, the gross profit margin of direct sales/distribution in 2022 will be 2.5% (0.8 pp)/6% (1.4 pp) respectively, of which the gross profit margin of direct e-commerce channels will be 3.1%; In terms of expense ratio, the company's total expense ratio was 1.4%, which was flat year-on-year. Looking at the spin-off, the sales expense ratio/administrative expense ratio/R&D expense ratio/financial expense ratio are 1% (+0pp)/0.3% (+0pp)/0.1% (+0pp)/0.1% (-0.1 pp) respectively, and the cost control is relatively stable. On the whole, the company's net in 2022<span>Interest rates</span>It was 1.6%, a year-on-year increase of 0.1 pp. In the first quarter of 2023, the company's gross profit margin was 4%, a year-on-year decrease of 0.1 pp. The total expense ratio was 0.9%, a year-on-year decrease of 0.3 pp; Among them, the sales expense ratio/administrative expense ratio/R&D expense ratio/financial expense ratio were 0.6%/0.2%/0%/0% respectively. Except for the sales expense ratio, which decreased by 0.3 pp year-on-year, the rest remained flat year-on-year. Taken together, the company's net profit margin in 2023Q1 was 1.9%, a year-on-year increase of 0.1 pp.</p><p>The sales structure has been optimized, and North China has the fastest growth under a low base. In 2022, the company's gold products/K gold jewelry products/brand usage fees/brand management fees will be 46.2 billion yuan (-7.7%)/480 million yuan (13.4%)/80 million yuan (-5.8%)/100 million yuan respectively (73.1%), accounting for 98%/1%/0.2%/0.2% of revenue respectively.</p><p>Specifically, the production/sales volume of gold products in 2022 will be 124.8 tons, a year-on-year decrease of 13.5%/12.5% respectively, mainly due to the impact of consumption scenarios and the pressure on consumer demand under the impact of the epidemic in 2022. With the repair of offline consumption scenarios and the improvement of consumer confidence, gold consumption continues to pick up, and performance is expected to usher in improvement. In terms of regions, in 2022, East China/North China/Central China/Southwest China/South China/Northwest China/Northeast China will achieve revenue of 23.34 billion yuan/9.39 billion yuan/3.27 billion yuan/3.05 billion yuan/3.89 billion yuan/2.09 billion yuan/1.84 billion yuan respectively,-0.7%/48.5%/-15.7%/-10%/-56.6%/-13.9%/-14.7% year-on-year respectively.</p><p>Direct sales have strong resilience, and distribution channels continue to be optimized. According to the sales model, in 2022, the company's direct sales/distribution will contribute 28.54 billion yuan (-5.5%)/18.32 billion yuan (-10.4%) in revenue, accounting for 60.9% (+1.3 pp)/39.1% (-1.3 pp) in revenue. 1.3 pp). Specifically, in 2022, the number of direct sales channels will expand by 14 to 105 against the trend, which is one of the reasons for the strong performance resilience of direct sales channels; The company's distribution channels continued to be optimized, and the number of stores decreased by 79 to 3,642 compared with the beginning of the year.</p><p>Actively deploying cultivation diamonds is expected to create a second growth curve. In 2022, the company will strategically enter the cultivation diamond track, and plans to take a multi-pronged approach in the upstream and downstream of the industrial chain. On February 7, 2023, the company will establish a cultivation diamond (new material) promotion division, and actively build a cultivation diamond R&D and design center, display The delivery center and supply chain service center are expected to create the second largest growth curve.</p><p>Earnings forecast and investment advice. It is estimated that the EPS from 2023 to 2025 will be 0.61 yuan, 0.76 yuan, and 0.86 yuan respectively, and the corresponding PE will be 20 times, 16 times, and 14 times respectively, maintaining a \"hold\" rating.</p><p>Risk warning: the risk of gold price fluctuation; The risk of increased competition in the industry; The risk that the company will open stores less quickly than expected.</p><p></article></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230426201228842c0d30&s=b\">西南证券股份有...</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"600916":"中国黄金","BK0209":"零售"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230426201228842c0d30&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2330393679","content_text":"业绩摘要：公司发 布2022年年报及2023年一季报。2022年公司实现营收471.2亿元，同比下降7.2%；实现归母净利润7.7 亿元，同比下降3.7%。2023Q1 公司实现营收161.4 亿元，同比增长12.3%；实现归母净利润3 亿元，同比增长19.1%，业绩复苏势头明显。盈利能力与费控均较为稳健。2022年公司毛利率为3.9%，同比上升0.8pp，毛利率上升主要受益于公司主营产品盈利能力提升叠加品类结构优化。分产品来看，公司主营产品黄金产品/K 金珠宝类产品的毛利率分别为3.3%（+0.8pp）/22.2%（+6.4pp）；分销售模式来看，2022 年直销/经销毛利率分别为2.5%（+0.8pp）/6%（+1.4pp），其中直营电商渠道毛利率为3.1%；费用率方面，公司总费用率为1.4%，同比持平。分拆来看，销售费用率/管理费用率/研发费用率/财务费用率分别为1%（+0pp）/0.3%（+0pp）/0.1%（+0pp）/0.1%（-0.1 pp），费控较为稳健。综合来看，2022 年公司净利率为1.6%，同比上升0.1pp。2023年一季度公司毛利率为4%，同比下降0.1pp。总费用率为0.9%，同比下降0.3pp；其中销售费用率/ 管理费用率/ 研发费用率/ 财务费用率分别为0.6%/0.2%/0%/0%，除销售费用率同比下降0.3pp 外，其余同比持平。综合来看，2023Q1 公司净利率为1.9%，同比提升0.1pp。销售结构有所优化，低基数下华北地区增长最快。2022年公司黄金产品/K 金珠宝产品/品牌使用费/品牌管理费分别为462 亿元（-7.7%）/4.8亿元（+13.4%）/0.8 亿元（-5.8%）/1亿元（+73.1%），营收占比分别为98%/1%/0.2%/0.2%。具体来看，2022 年黄金产品生产量/销售量均为124.8 吨，分别同比下滑13.5%/12.5%，主要受2022年在疫情冲击下消费场景及消费需求承压影响，2023年以来随着线下消费场景修复及消费信心改善，黄金消费持续回暖，预计业绩会迎来改善。分地区来看，2022 年华东/华北/华中/西南/华南/西北/东北地区分别实现营收233.4亿元/93.9亿元/32.7亿元/30.5亿元/38.9亿元/20.9亿元/18.4亿元，分别同比-0.7%/+48.5%/-15.7%/-10%/-56.6%/-13.9%/-14.7%，华北地区在低基数下增长最快。直营韧性较强，经销渠道持续优化。按销售模式来看，2022 年公司直销/经销分别贡献收入285.4 亿元（-5.5%）/183.2 亿元（-10.4%），营收占比分别为60.9%（+1.3pp）/39.1%（-1.3pp）。具体来看，2022 年直营渠道逆势扩张14家至105家，是直营渠道业绩韧性较强的原因之一；公司经销渠道持续优化，门店数量较年初净减少79家至3642 家。积极布局培育钻，有望打造第二增长曲线。2022 年公司战略性切入培育钻赛道，计划在产业链上下游多管齐下，并于2023 年2 月7日成立培育钻石（新材料）推广事业部，积极建设培育钻研发设计中心、展示交付中心和供应链服务中心，有望打造第二大增长曲线。盈利预测与投资建议。预计2023-2025 年EPS 分别为0.61 元、0.76 元、0.86元，对应PE 分别为20 倍、16 倍、14 倍，维持“持有”评级。风险提示：金价波动的风险；行业竞争加剧的风险；公司开店速度不及预期的风险。","news_type":1,"symbols_score_info":{"600916":0.9}},"isVote":1,"tweetType":1,"viewCount":1228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}